Sugemalimab plus chemo boosts lung cancer survival, trial reveals
pharmaphorum
JANUARY 19, 2022
EQRx’s GEMSTONE-302 study evaluated the efficacy and safety of the investigational anti-PD-L1 antibody, sugemalimab, in combination with chemotherapy as a first-line treatment for patients with stage four non-small cell lung cancer (NSCLC), versus using chemotherapy alone. But prevalence still increased by 10% between 2008 and 2012.
Let's personalize your content